These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20028420)

  • 1. Reply to 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors' (Haemophilia 2009; 15: 3-10).
    Hedner U
    Haemophilia; 2010 Mar; 16(2):372-3. PubMed ID: 20028420
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
    Berntorp E
    Haemophilia; 2009 Jan; 15(1):3-10. PubMed ID: 19016901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A.
    Duan X; Tang M; Zhang J; Yu H; Xu R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors.
    Ewenstein BM; Wong WY; Schoppmann A
    Haemophilia; 2010 Jan; 16(1):179-80. PubMed ID: 19702885
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of haemophilic arthropathy in haemophilic children with inhibitors.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Nov; 14 Suppl 6():1-3. PubMed ID: 19134025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR
    Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract]   [Full Text] [Related]  

  • 9. Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy.
    Johansen RF; Sørensen B; Ingerslev J
    Haemophilia; 2006 Mar; 12(2):190-7. PubMed ID: 16476097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
    Hough RE; Hampton KK; Preston FE; Channer KS; West J; Makris M
    Br J Haematol; 2000 Dec; 111(3):974-9. PubMed ID: 11122162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M; Coppola A; Tagliaferri A; Lippi G
    Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
    Ingerslev J; Sørensen B
    Br J Haematol; 2011 Oct; 155(2):256-62. PubMed ID: 21895627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
    Berntorp E; Collins P; D'Oiron R; Ewing N; Gringeri A; Négrier C; Young G
    Haemophilia; 2011 Jan; 17(1):e202-10. PubMed ID: 20825500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and monitoring of bypassing agent therapy.
    Hoffman M; Dargaud Y
    J Thromb Haemost; 2012 Aug; 10(8):1478-85. PubMed ID: 22632160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When should prophylaxis therapy in inhibitor patients be considered?
    Young G; Auerswald G; Jimenez-Yuste V; Konkle BA; Lambert T; Morfini M; Santagostino E; Blanchette V
    Haemophilia; 2011 Sep; 17(5):e849-57. PubMed ID: 21418444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA.
    Miranda GG; Rodgers GM
    Haemophilia; 2009 Jan; 15(1):383-5. PubMed ID: 18759746
    [No Abstract]   [Full Text] [Related]  

  • 18. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors.
    Majumdar G; Savidge GF
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1031-3. PubMed ID: 8148476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of difficult-to-treat inhibitor patients.
    Giangrande PL; Escobar MA
    Haemophilia; 2010 May; 16 Suppl 3():52-7. PubMed ID: 20586803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.